Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study

Jun Xiao1,2*, Anders P. Persson3, Gunnar Engström2 and Linda S. B. Johnson2*

Abstract

Background: Frequent supraventricular arrhythmia is associated with increased incidence of atrial fibrillation. However, it is unknown whether the prognostic significance of supraventricular arrhythmia is modified by plasma levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) or troponin T (TnT). This study examined the interrelationships between NT-proBNP, TnT levels and frequent supraventricular arrhythmia, and whether these biomarkers and a measure of frequent supraventricular arrhythmia could improve risk assessment for incidence of AF.

Methods: Supraventricular extrasystoles (SVEs) and supraventricular tachycardias were assessed from 24-h electrocardiograph recordings in 373 individuals initially without AF. Elevated NT-pro-BNP, TnT and SVEs was defined as a measurement in the top quartile of the study population distribution. Incident cases of AF were retrieved by linkage with the Swedish National Patient Register.

Results: During a mean follow-up of 15.4 years, 88 subjects had a diagnosis of AF. After multivariable adjustment, individuals with both elevated NT-proBNP and frequent SVEs had a significantly increased incidence of AF, compared to subjects without elevated NT-proBNP or frequent SVEs (hazard ratio (HR) 4.61, 95% confidence interval (CI) 2.45–8.69), and compared to individuals with either elevated NT-proBNP or frequent SVEs (both P < 0.05). HRs for frequent SVEs alone or elevated NT-proBNP alone were 2.32 (95% CI 1.33–4.06) and 1.52 (95% CI 0.76–3.05), respectively. The addition of NT-pro-BNP and SVEs to a validated risk prediction score for AF, CHARGE-AF, resulted in improved prediction (Harrell’s C 0.751 (95% CI 0.702–0.799) vs 0.720 (95% CI 0.669–0.771), P = 0.015).

Conclusion: Subjects with both elevated NT-proBNP and frequent SVEs have substantially increased risk of AF, and the use of these variables could improve long-term prediction of incident AF.

Keywords: Atrial fibrillation, Supraventricular extrasystole, Premature atrial contractions, Supraventricular tachycardia, NT-proBNP, Troponin T

Introduction

Atrial fibrillation (AF) is the most common sustained arrhythmia, especially among the elderly, and is associated with increased mortality and morbidity [1–3]. Improved risk assessment and early identification of individuals with high risk of AF could improve stroke prevention and lead to important public health benefits. Even though there are currently no validated prevention...
programs for AF, recent research indicates that early stages of the disease could be reversible [4, 5]. Furthermore, since AF can be asymptomatic, stroke events associated with AF may occur before AF is diagnosed. If individuals with high AF risk could be identified, this could enable repeated or prolonged electrocardiogram (ECG) monitoring, and early anticoagulation in order to prevent stroke.

Although the pathophysiology of AF is complex, considerable advances have been made in understanding the underlying pathophysiological mechanisms. There is convincing evidence that atrial myopathy, a state of atrial structural and electrical remodeling, precedes the development of AF [6, 7]. Structural remodeling includes atrial dilation and myocardial damage. This may result in elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T (TnT) [8, 9], both of which have been linked to a greater risk of AF [10, 11]. Electrical remodeling, on the other hand, can be measured by increased frequency of supraventricular extrasystoles (SVEs) and supraventricular tachycardias (SVTs), which are also highly related to AF risk [12–16]. It is plausible, therefore, that subjects with both elevated NT-pro-BNP or TnT and frequent supraventricular extrasystoles could have substantially increased risk of AF.

The CHARGE-AF score is a well validated risk score for prediction of AF, and a simplified form of the score can be calculated from clinically available parameters [17, 18]. The aim of this study was to examine whether the predictive value for incident AF is improved by combining SVEs and NT-proBNP or TnT levels, and if these risk factors add predictive information on top of the validated CHARGE-AF risk score for AF.

Methods

Study population

The study population was derived from the population-based, prospective Malmö Diet and Cancer Study cohort, which has been described elsewhere [16], and which consists of 30,446 individuals (age range 44–73 years, 39.8% men) recruited during the period of 1991–1996. A subsample consisting of 6103 individuals were randomly invited to receive additional screening in a cardiovascular sub-study. In 1998–2000, a re-examination was performed for 909 individuals from the cardiovascular sub-study. These individuals were randomly invited after stratification for degree of insulin resistance, as measured by the homeostasis model assessment for insulin resistance (HOMA-IR, calculated as fasting insulin (mIU/l) fasting blood glucose (mmol/l)/22.5). High HOMA-IR was slightly oversampled (15% from each of quartiles 1 and 2, 30% from quartile 3, and 40% from quartile 4). Of the 909 individuals, a random subsample of 388 individuals underwent 24hECG screening (age range 53–74, 45.6% men). The study conforms to the declaration of Helsinki. Subjects with inadequate 24hECG recordings (n = 5), a diagnosis of AF (n = 6), missing NT-proBNP and TnT results (n = 4) were excluded; resulting in a final study population consisting of 373 subjects in total. Due to missing data for HOMA-IR score (n = 7), low density lipoprotein (LDL) (n = 1), and height and weight (n = 1), multivariable models included 364 subjects (Additional file 1: Supplementary Figure 1).

Data collection

Physical examination was performed for all subjects at baseline. Height and weight were measured standing in light indoor clothing, using a fixed stadiometer and a balance beam scale. Blood pressure was measured after 10 min supine rest, using a sphygmomanometer with a modifiable cuff. All patients completed an extensive self-administered questionnaire, from which current smoking status was retrieved. History of diabetes, coronary events, and heart failure were obtained through a combination of information from questionnaires and data from hospital registers. Blood samples were drawn after overnight fast and analyzed using standard laboratory procedures at the Malmö University Hospital. The samples were stored at −70 °C. Plasma samples were analyzed by electrochemiluminescence using R-PLEX human NT-proBNP and R-PLEX human TnT (cardiac) assays (Meso Scale Discovery, Gaithersburg, MD) on a Sector S600 instrument at the Clinical Biomarkers Facility, SciLifeLab, Uppsala, Sweden. The NT-proBNP assay was run at a 1:10 dilution (average dynamic range 1.1 pg/ml–10,000 pg/ml) whereas Troponin T was run neat (average dynamic range 4.4 pg/ml to 500 pg/ml).

24-h ECG

All patients underwent a 24-hour 3-lead (X, Y, Z coupling) Holter ECG recording, with 256-Hz sampling rate, for arrhythmia detection, which has been described before [16]. The equipment used was Life card CF digital Holter recorder with 12-bit resolution (Spacelabs Health care, Issaquah, WA). Findings were classified using the Pathfinder S.L analysis tool (Spacelabs Healthcare). All ECG recordings were manually verified. Mean analysis time was 23.2 h, with a standard deviation (SD) of 1.2 h. SVEs was defined as a premature narrow complex beat preceded by a normal sinus beat. Three or more consecutive SVEs with a heart rate ≥ 100 beats per minute was defined as a SVT.

CHARGE-AF risk score

The CHARGE-AF risk score was calculated for each individual according to previously described
End-point ascertainment
Subjects were followed until first AF diagnosis (diagnosis codes 427D for the 9th revision of the International Classification of Diseases (ICD-9), and 148 for the 10th revision (ICD-10)), death, emigration, or end of the study (December 31, 2018), whichever came first. Atrial flutter was not distinguished from AF, due to the similarities between these diagnoses [20]. All endpoints were retrieved from the National Patient Register administered by the Swedish National Board of Health and Welfare, which covers all inpatient diagnoses since the year 1987 and all hospital outpatient diagnoses since the year 2000. A validation study of the AF cases in the Malmö Diet and Cancer study showed an accuracy of 95% [21]. The conventional duration of AF for diagnosis is 30 s in Sweden. The regional ethics review board in Lund has approved the study (LU 51/90).

Statistical methods
All analyses were performed using SPSS 25.0 and R 3.6.3. Negative binominal regression was used to estimate the relation between the numbers of SVEs per 24 h or SVTs per 24 h and per quartile increase in the NT-proBNP or TnT concentrations. Cox regression analyses were used to study the association between the combination of supraventricular arrhythmias and plasma biomarkers and incidence of AF. Elevated SVEs, SVTs, NT-proBNP, and TnT was defined as a measurement in the top quartile, corresponding to >129.18 SVEs/24 h, 3.06 SVTs/24 h, 32.80 pg/ml NT-proBNP and >1.38 pg/ml TnT. Elevated supraventricular activity (SVA) was defined as either the top quartile of SVEs or SVTs. Based on previous studies [16, 22], potential confounders which were related to both exposure and outcome were identified, and the following two pre-specified models were used. Model 1 adjusted for age and sex, and Model 2 additionally adjusted for current smoking, use of anti-hypertension medications, systolic blood pressure, LDL, natural log of HOMA-IR, height, and weight. A P-value below 0.05 denoted statistical significance.

Results
Baseline characteristics
The mean age at baseline was 64.0 ± 5.9 years. Of the 373 included individuals, 203 (54.4%) were women. At baseline 22.8% (n = 85) of study participants were smokers. Information of baseline characteristics is presented in Table 1.

Plasma biomarkers, supraventricular arrhythmias and incidence of AF
During a mean follow-up time of 15.4 years, 88 subjects were diagnosed with AF (cumulative incidence 23.6%). The number of SVEs and SVTs in 24 h were positively associated with quartiles of NT-proBNP and TnT concentrations (Fig. 1, Additional file 1: Supplementary Table 1). After multivariable adjustment NT-proBNP and TnT were related to the number of SVEs in 24 h (Odds ratio (OR)NT-proBNP = 1.64, 95% confidence interval (CI) 1.33–2.02; ORTnT = 1.33, 95% CI 1.10–1.60, both per quartile increase; Additional file 1: Supplementary Table 1). A similar association was observed for SVTs in 24 h: ORNT-proBNP = 1.60, 95% CI 1.27–2.02; ORTnT = 1.33, 95% CI 1.03–1.62 per quartile increase (Additional file 1: Supplementary Table 1).

The association between the combinations of NT-proBNP and supraventricular arrhythmias with risk of AF is reported in Table 2. After multivariable adjustment individuals with both elevated NT-proBNP and elevated SVEs had the highest risk of incident AF, compared to subjects with normal values for both SVEs and NT-proBNP, and compared to subjects with either elevated SVEs or elevated NT-pro-BNP, for which groups an intermediate risk was observed. Similar results were found for combinations of NT-proBNP and SVTs, as well as NT-proBNP and SVA.
Results for the association of combinations of TnT and supraventricular arrhythmias with incident AF are presented in Table 3. The highest risk of AF was found among individuals with both elevated TnT and supraventricular arrhythmias compared to subjects without.

**NT-proBNP, SVEs, and CHARGE-AF score**

The relationship between NT-pro-BNP, SVEs and incidence of AF was also analyzed for elevated and normal levels of CHARGE-AF score. The combination of both elevated NT-pro-BNP and frequent SVEs was more common among subjects with an elevated CHARGE-AF score; 4.5% in the lower two tertiles compared to 19.0% in the top tertile ($\chi^2$ test value = 20.005, $P < 0.001$). Incidence of AF in individuals with high CHARGE-AF and both elevated NT-proBNP and elevated SVEs was 50.5 per 1000 as compared to 12.7 per 1000 for those with high CHARGE-AF score and normal SVEs and NT-proBNP (Fig. 2 and Additional file 1: Supplementary Figure 2).

The CHARGE-AF risk score had good discrimination for incident AF (C-statistic 0.720, 95% CI 0.669–0.771; Table 4). The highest C-statistic was found for a model including CHARGE-AF risk score, elevated NT-proBNP, and frequent SVEs: 0.751 (95% CI 0.702–0.799); this was significantly higher than CHARGE-AF score alone ($P = 0.015$; Table 4). Similarly, the category-free NRI also showed significant improvements.
in prediction of AF when elevated NT-proBNP and frequent SVEs were simultaneously added on top of CHARGE-AF score (NRI = 0.300, 95% CI 0.166–0.452; Table 4).

**Discussion**

Findings from the current study suggest that subjects with both elevated NT-pro-BNP or TnT and frequent supraventricular ectopy have a markedly increased risk of incident AF. Among the 9.1% of the population with both elevated NT-pro-BNP and frequent SVEs, the absolute risk of incident AF was almost 5% per year, and by the end of follow-up more than half of the subjects in this group had been diagnosed with atrial fibrillation. This risk was similar regardless of CHARGE-AF score. Future studies of primary prevention of AF could focus on this population. Patients with AF are at risk of adverse outcomes, such as heart failure, thrombo-embolism and impaired cognitive function, and this results in substantial mortality and morbidity [24]. Earlier detection and prevention could therefore contribute to reduced AF-associated morbidity, mortality, and medical costs [25].

Both SVE and NT-pro-BNP are established predictors of AF. SVEs have been shown to be associated with incident AF in several cohorts sampled from American, European and Asian populations [14–16, 26]. SVT frequency is associated with incidence of AF independently of symptomatic cardiovascular disease in this cohort and the Copenhagen Holter Study [14, 16]. It is plausible that frequent supraventricular ectopic activity is a marker of existing electrical remodeling, a component of the emerging concept of atrial myopathy which is also characterized by structural remodeling [27]. Structural remodeling is characterized by atrial dilatation, as well as atrial strain [7], and these changes increase the secretion of NT-proBNP from atrium [6, 28–31]. Tissue fibrosis is another characteristic of structural remodeling; this observed in parallel with myocardial apoptosis or necrosis [32]. Troponin T, which is released during cardiomyocyte damage and could possibly reflect fibrosis, is also related to incident AF [11, 33, 34]. This study found
a correlation between supraventricular arrhythmias and plasma biomarkers levels, and that the combination of NT-pro-BNP and frequent SVEs was more common among subjects with elevated CHARGE-score, which supports the idea that atrial myopathy is caused by established AF risk factors, and that intervention against modifiable risk factors may slow the progression from atrial myopathy to AF.

Several risk scores and equations have been developed for the prediction of AF [17]. Extensions of these models include information on blood biomarkers, echocardiographic and electrocardiographic measurements, or genetic variants, beyond the information provided by clinical variables [17]. The present study indicates that a model based on current knowledge of the pathophysiological mechanisms behind AF has the potential to further improve AF prediction, and identify subjects with a markedly increased AF risk. This group could potentially benefit from primary prevention and efforts for early detection of AF in order to prevent stroke.

**Strengths and limitations**

There are several strengths of present study. The mean age of the study population is relevant and corresponds to an age at which the incidence of AF is relatively high, but before the onset of the majority of AF cases [35]. The endpoint was retrieved from comprehensive patient registers that cover in- and outpatient hospital diagnoses in Sweden. Only two subjects were lost to follow-up due to emigration from Sweden. The registers do not cover AF patients that are treated in primary care only and it has been estimated that specificity and sensitivity is 93% and 80%, respectively, for an AF diagnosis in these registers [36]. Also, some incident cases with asymptomatic AF may have been missed. However, the high overall cumulative incidence of AF in this study (23.6%) is similar to the life-time risk of AF calculated in other-studies [1, 37], implying that few cases of incident AF have been missed.

The sample size of the population was limited, and in the case of weaker associations this would have resulted in a risk of type II error. The population was oversampled of individuals with insulin resistance and as such, this could be regarded as a population with an increased cardiometabolic risk. However, the results were adjusted

### Table 3 Incidence of AF by occurrence of elevated TnT and frequent supraventricular arrhythmias

| N = 373 | Subjects | Incident AF cases | Incidence rate (per 1000 person-years) | Model 1 h (95%CI) | Model 2 h (95%CI) |
|---------|---------|------------------|----------------------------------------|------------------|------------------|
| **TnT and SVEs** | Non-elevated TnT, infrequent SVEs | 225 | 37 | 10.00 | Ref | Ref |
| | Elevated TnT, infrequent SVEs | 54 | 10 | 12.76 | 1.09 (0.54, 2.20) | 0.96 (0.47, 1.97) |
| | Non-elevated TnT, frequent SVEs | 55 | 19 | 23.69 | 2.24 (1.28, 3.92) | 2.30 (1.30, 4.09) |
| | Elevated TnT, frequent SVEs | 39 | 22 | 46.69 | 3.71 (2.11, 6.51) | 3.07 (1.74, 5.41) |
| | Interaction TnT *SVEs | | | | P = 0.377 | P = 0.501 |
| **TnT and SVTs** | Non-elevated TnT, infrequent SVTs | 221 | 33 | 9.18 | Ref | Ref |
| | Elevated TnT, infrequent SVTs | 54 | 14 | 18.22 | 1.66 (0.88, 3.12) | 1.43 (0.75, 2.74) |
| | Non-elevated TnT, frequent SVTs | 59 | 23 | 25.27 | 2.40 (1.40, 4.11) | 2.29 (1.31, 4.02) |
| | Elevated TnT, frequent SVTs | 39 | 18 | 37.02 | 2.99 (1.65, 5.45) | 2.58 (1.40, 4.76) |
| | Interaction TnT *SVTs | | | | P = 0.528 | P = 0.599 |
| **TnT and SVA** | Non-elevated TnT, non-elevated SVA | 198 | 30 | 9.22 | Ref | Ref |
| | Elevated TnT, non-elevated SVA | 50 | 10 | 13.79 | 1.27 (0.62, 2.62) | 1.07 (0.51, 2.24) |
| | Non-elevated TnT, elevated SVA | 82 | 26 | 20.79 | 1.97 (1.16, 3.35) | 1.91 (1.10, 3.33) |
| | Elevated TnT, elevated SVA | 43 | 22 | 41.55 | 3.35 (1.87, 5.99) | 2.85 (1.58, 5.13) |
| | Interaction TnT *SVA | | | | P = 0.533 | P = 0.493 |

Model 1: age, sex adjusted (n = 373)
Model 2: Model 1 + smoking status + anti-hypertension medications + systolic blood pressure + LDL + natural log of HOMA-IR + height + weight (n = 364)

Frequent SVEs, SVTs, and elevated TnT were defined as the top quartile, corresponding to > 129.18 SVEs/24 h, 3.06 SVTs/24 h and > 1.38 pg/ml TnT, respectively; elevated SVA was defined as frequent SVEs or SVTs

AF atrial fibrillation, TnT troponin T, SVEs supraventricular extrasystoles, SVTs supraventricular tachycardias, SVA supraventricular activity

† P < 0.05 when compared to group with elevated TnT and frequent SVEs
‡ P < 0.05 when compared to group with elevated TnT and elevated SVA
In order to assess the risk of residual confounding, the E value was calculated [39] which estimates how strong any unmeasured confounder must be to remove the significance of the observed main results. The E value for the association between the combination of elevated NT-proBNP with frequent SVEs and AF incidence was 5.06 with the confidence limit of 3.11, suggesting that the observed association could be removed by an unmeasured confounder, which is related to both independent and dependent variable with a relative risk of 5.06, indicating a high robustness of current results.

**Conclusions**
We conclude that subjects with both frequent SVEs or SVTs and elevated NT-pro-BNP, are at markedly increased risk of AF. A combination of biomarkers and frequent SVEs or SVTs could improve long-term prediction of incident AF.

**Abbreviations**
AF: Atrial fibrillation; ECG: Electrocardiogram; NT-proBNP: N-terminal pro-brain natriuretic peptide; TnT: Troponin T; SVEs: Supraventricular extrasystoles; SVTs: Supraventricular tachycardias; HOMA-IR: Homeostasis model assessment for insulin resistance; LDL: Low density lipoprotein; CI: Confidence interval; OR: Odds ratio; HR: Hazard ratio; NRI: Net reclassification improvement.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12872-021-01942-6.

**Additional file 1: Supplementary Figure 1** Individuals included in this research. **Supplementary Figure 2** Incidence of atrial fibrillation in relation to a combination of elevated NT-proBNP and frequent SVEs. **Supplementary Table 1** Effect estimates of the association between number of SVEs/SVTs and NT-proBNP/TnT.

**Table 4** C-statistics and category free net reclassification improvement (NRI) of predictive models for incident AF†

|                      | C-statistic (95%CI) | P for difference† | NRI                       |
|----------------------|---------------------|-------------------|---------------------------|
| CHARGE-AF score      | 0.720 (0.669, 0.771) | Reference         | Reference                 |
| Frequent SVEs        | 0.778 (0.703, 0.854) | 0.075             | −0.222 (−0.372, 0.059)    |
| Elevated NT-proBNP   | 0.726 (0.635, 0.817) | 0.448             | −0.277 (−0.427, −0.001)   |
| Elevated TnT         | 0.705 (0.610, 0.799) | 0.376             | −0.258 (−0.425, −0.098)   |
| Frequent SVEs + elevated NT-proBNP | 0.768 (0.704, 0.832) | 0.084             | −0.126 (−0.334, 0.158)    |
| CHARGE-AF score + frequent SVEs | 0.743 (0.694, 0.793) | 0.020             | 0.311 (0.182, 0.440)      |
| CHARGE-AF score + elevated NT-proBNP | 0.734 (0.685, 0.783) | 0.110             | 0.288 (−0.028, 0.385)     |
| CHARGE-AF score + elevated TnT | 0.717 (0.664, 0.769) | 0.392             | 0.201 (−0.176, 0.362)     |
| CHARGE-AF score + frequent SVEs + elevated NT-proBNP | 0.751 (0.702, 0.799) | 0.015             | 0.300 (0.166, 0.452)      |

Frequent SVEs, elevated NT-proBNP and elevated TnT were defined as the top quartile, corresponding to > 129.18 SVEs/24 h and 32.80 pg/ml NT-proBNP, respectively.

AF atrial fibrillation, SVEs supraventricular extrasystoles, NT-proBNP N terminal pro B type natriuretic peptide; TnT troponin T
† Net reclassification improvement was calculated for a 15-year AF risk prediction
§ P for difference in C-statistics compared to the Reference group

for HOMA-IR and results were still statistically significant. There are some unmeasured factors which may lead to residual bias, such as other biomarkers. For example, von Willebrand factor is associated with incident AF [38].
Acknowledgements
The authors wish to thank all the participants and all medical and nursing staff for making this study possible. The SciLifeLab laboratory, Uppsala, Sweden, is acknowledged for assistance in biomarker analysis.

Authors’ contributions
GE and LJ designed the study; GE and LJ acquired the data; JX, GE and LJ performed the statistical analysis and interpreted the results; JX drafted the first version of the manuscript; AP, GE and LJ read and critically reviewed the final version of the manuscript. All authors read and approved the final manuscript.

Funding
Open access funding provided by Lund University. Jun Xiao is supported by the China Scholarship Council (Grant No. 201908350096). Dr Johnson is supported by governmental funding within the Swedish National Health Services, the Swedish Society of Medicine (Grant No. SLS-888281), the Swedish Society of Cardiology; the Swedish Heart and Lung Association (Grant No. FA 2018:50) and the Bergqvist Foundation (Grant No. 139645). Dr. Johnson and Dr. Engstroem are supported by the Swedish Heart and Lung Foundation (Grant Nos. 20180211, 20190354, 20190224 and 20190294), Sparbanksstiftelsen Fårs & Frosta and Swedish Research Council (2019–01236).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request, or upon request from the data access group of Malmo Diet and Cancer study.

Declarations
Ethics approval and consent to participate
All participants provided informed consent and the studies were approved by The Ethics Committee of Lund University. The study conforms to the declaration of Helsinki.

Consent for publication
Not applicable.

Clinical relevance and future perspective
Those with both frequent supraventricular arrhythmia and elevated NT-proBNP have a high risk of future atrial fibrillation. This group could potentially benefit from primary prevention and efforts for early detection of AF.

Competing interests
The authors declare no competing interests.

Received: 6 October 2020 Accepted: 1 March 2021
Published online: 12 March 2021

References
1. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.
2. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D’Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229–34.
3. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Incidence of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.
4. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ABREAST-AF cohort study. J Am Coll Cardiol. 2014;64:2222–31.
5. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVent and reCoLective (PreeCoL) of weight-loss and risk factor modification on Atrial fibrillation: the REVERSE-AF study. Europace. 2018;20:1929–35.
6. Casas-Arangl-Verzosa G, Gersh BJ, Tsang TS. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol. 2008;51:1–11.
7. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335–45.
8. Tsai JP, Sung KT, Su CH, Lai YH, Kuo YJ, Yun CH, et al. Diagnostic accuracy of left atrial remodelling and natriuretic peptide levels for preclinical heart failure. ESC Heart Fail. 2019;6:723–32.
9. Kawasati T, Sakai C, Harimoto K, Yamano M, Miki S, Kamitani T. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2013;112:867–72.
10. Svensen Berg E, Lindahl B, Berglund L, Eggers KM, Venge P, Zethelius B, et al. NT-proBNP is a powerful predictor for incident atrial fibrillation—validation of a multimarker approach. Int J Cardiol. 2016;222:74–81.
11. Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, et al. High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2015;169(31–8):e3.
12. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62–73.
13. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation. 2011;124:2264–74.
14. Binici Z, Intzalakis T, Nielsen OW, Køber L, Sayadjeh A. Excessive supraventricular tachyarrhythmia and increased risk of atrial fibrillation and stroke. Circulation. 2010;121:1904–11.
15. Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, Stein PK, et al. Atrial ectopy as a predictor of incident atrial fibrillation: a cohort study. Ann Intern Med. 2013;159:721–8.
16. Johnson LS, Juhlin T, Juul-Møller S, Hedblad B, Nilsson PM, Engstrom G. A prospective study of supraventricular activity and incidence of atrial fibrillation. Heart Rhythm. 2015;12:1988–904.
17. Alonso A, Norby FL. Predicting atrial fibrillation and its complications. Circ J. 2016;80:1061–6.
18. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e00102.
19. Christophersen IE, Yin X, Larson MG, Lubitz SA, Magnani JW, McManus DD, et al. A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study. Am Heart J. 2016;178:45–54.
20. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol. 2008;51:779–86.
21. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmö Diet and Cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2010;25:95–102.
22. Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136:583–98.
23. Schroeder MS, Cullance AC, Quackenbush J, Haibe-Kains B. survcomp: an R/Bioconductor package for performance assessment and comparison of survival models. Bioinformatics. 2011;27:3206–8.
24. Kirchhoff P, Benussi S, Kotecha D, Ahsisson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.
25. Bonani G, Proietti M. Atrial fibrillation prevention: an appraisal of current evidence. Heart. 2018;104:982–7.
26. Chong BH, Pong V, Lam KF, Liu S, Zuo ML, Lau YF, et al. Frequent premature atrial complexes predict new occurrence of atrial fibrillation and adverse cardiovascular events. Europace. 2012;14:942–7.
27. Goldberger JJ, Arora R, Green D, Greenland P, Lee DC, Lloyd-Jones DM, et al. Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation. 2015;132:278–91.
28. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J. 2006;27:1648–50.
29. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Grottiener JS, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120:1768–74.
30. Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, et al. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial
fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart. 2013;99:1832–6.
31. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenstaller NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712–9.
32. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9.
33. Eggert KM, Al-Shakarchi J, Berglund L, Lindahl B, Siegbahn A, Wallentin L, et al. High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J. 2013;166:541–8.
34. Anegawa T, Kai H, Adachi H, Hirai Y, Enomoto M, Fukami A, et al. High-sensitive troponin T is associated with atrial fibrillation in a general population. Int J Cardiol. 2012;156:98–100.
35. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461–8.
36. Baturova MA, Lindgren A, Carlson J, Shubik-YV, Bertil Olsson S, Platunov PG. Atrial fibrillation in patients with ischaemic stroke in the Swedish national patient registers: how much do we miss? Europace. 2014;16:1714–9.
37. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–6.
38. Gragnano F, Golia E, Natale F, Bianchi R, Pariggiano I, Crisci M, et al. Von Willebrand factor and cardiovascular disease: from a biochemical marker to an attractive therapeutic target. Curr Vasc Pharmacol. 2017;15:404–15.
39. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268–74.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.